An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly

Endocrine Journal

Volumn 46, Issue 1, 1999, Pages 193-198

  Lin, Jen Der ^a   Lee, Shih Tseng ^b   Weng, Hsiao Fen ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Bromocriptine; GH; Insulin like growth factor I; Somatostatin

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; OCTREOTIDE;

ABDOMINAL PAIN; ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DIARRHEA; FEMALE; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HUMAN; HYPOPHYSECTOMY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE;

EID: 0032894105     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.46.193     Document Type: Article

References (29)

1. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Iddertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 41: 95-102.
2. Bate AS, Van't Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86: 293-299.
3. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12: 71-79.
4. Wright AD, Hill DM, Lowy C, Fraser TR (1970) Mortality in acromegaly. Q J Med 39: 1-16.
5. Besser GM, Wass JAJ, Throner MO (1980) Bromocriptine in the medical management of acromegaly. Adv Biochem Psychopharmacol 23: 191-198.
6. Moreau JP, De Feudis FU (1987) Pharmacological studies of somatostatin and somatostatin analogs; therapeutic advances and perspectives. Life Sci 40: 419-437.
7. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76: 721-727.
8. Morange I, De Boisvilliers F, Chanson P, Lucas B, Dewailly D, Catus F, Thomas F, Jaquet P (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79: 145-151.
9. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132: 320-325.
10. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petrocini M, Liuzzi A, del Pozo E (1987) Medical treatment of acromegaly with SMS 201-995, somatostatin analog: A comparison with bromocriptine. J Clin Endocrinol Metab 64: 447-453.
11. Halse J, Harris AG, Kvistborg A, Kjartansson O, Hanssen E, Smiseth O, Djosland O, Hass G, Jervell J (1990) A randomized study of SMS 201 995 versus bromocriptine treatment in acromegaly: Clinical and biochemical effects. J Clin Endocrinol Metab 70: 1254-1261.
12. Tolis G (1996) The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism 45: 109-110.
13. Page MD, Millward ME, Hourihan M, Hall R, Scanlon NF (1990) Long-term treatment of acromegaly with octreotide (Sandostatin). Horm Res 33 (Suppl 1): 20-31.
14. White MC, James RA, Chatterjee S, Mother M, Hall K, Dunne MJ, Baister ER, Kendall-Taylor P (1990) Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly. Horm Res 33 (Suppl 1): 13-19.
15. AJ-Maskari M, Gebbie J, Kendall-Taylor P (1996) The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol 45: 415-421.
16. Heiman ML, Murphy WA, Coy DH (1987) Differential binding of somatostatin agonists to somatostatin receptors in brain and in adenohypophysis. Neuroendocrinol 45: 429-436.
17. Sassolas G, Khallah Y, Chagvialle JA, Cohen R, Merabet S, Casez JP, Calvet P, Cabrera P (1989) Effects of the somatostatin analogue BIM 23014 on the secretion of growth hormone, thyrotropin and digestive peptides in man. J Clin Endocrinol Metab 68: 239-246.
18. Evers B, Parekh D, Townsend C, Thompson JC (1991) Somatostatin and analogues in the treatment of cancer: A review. Ann Surg 213: 190-198.
19. Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18-22.
20. Marek J, Vaclav H, Michal K, Vlasta J, France C, Francois T (1994) Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 131: 20-26.
21. Parmar H, Bogden A, Mollard M, de Rouge B, Phillips RH, Lightman SL (1989) Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 16: 95-115.
22. Heldin CH, Westermark B (1984) Growth factors: Mechanism of action and relation to oncogenes. Cell 37: 9-20.
23. Goustin AS, Leof EB, Shipley GD, Moses HL (1986) Growth factors and cancer. Cancer Res 46: 1015-1029.
24. Stoscheck CM, King LE Jr (1986) Role of epidermal growth factor in carcinogenesis. Cancer Res 46: 1030-1037.
25. Kirkegaard P, Olsen PS, Nexo, Holst JJ, Poulsen SS (1984) Effect of vasoactive intestinal polypeptide and somatostatin on secretion of epidermal growth factor and bicarbonate from Brunner's gland. Gut 25: 1225-1229.
26. Venier A, De Simone C, Forni L, Ghirlanda G, Uccioli L, Serri F, Frati L (1988) Treatment of severe psoriasis with somatostatin: Four years of experience. Arch Dermatol Res 280 (Suppl): S51-S54.
27. Dullaart RPF, Meijer S, Marbach P, Sluiter WJ (1992) Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest 22: 494-502.
28. Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metab Clin Exp 41 (Suppl 2): 51-58.
29. Giusti M, Gussoni G, Cuttica CM, Giordano G (1996) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. J Clin Endocrinol Metab 81: 2089-2097.